[Economic evaluation of a new treatment for rheumatoid arthritis].
In recent years, new biologic agents have been approved for the treatment of rheumatoid arthritis. These agents may yield clear clinical benefits but impose greater costs than standard treatment. Economic evaluations have been used to provide evidence for the cost-effectiveness of treatment. We described two approaches to the cost-effectiveness analysis of the treatment of rheumatoid arthritis-micro-level economic evaluation based on quality-adjusted life years (QALYs) and macro-level economic evaluation based on disability-adjusted life years (DALYs).
Suka
Machi
M
Department of Preventive Medicine, St. Marianna University School of Medicine.
Yoshida
Katsumi
K
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000191:economics; D000911:Antibodies, Monoclonal / Q000191:economics*; D018501:Antirheumatic Agents / Q000191:economics*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D003362:Cost-Benefit Analysis; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics*; D000069285:Infliximab; D007555:Isoxazoles / Q000191:economics; D000077339:Leflunomide; D008727:Methotrexate / Q000191:economics; D019057:Quality-Adjusted Life Years; D018124:Receptors, Tumor Necrosis Factor
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007555:Isoxazoles; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000077339:Leflunomide; D000068800:Etanercept; D008727:Methotrexate